Skip to main content
Clinical Trials/NCT07560254
NCT07560254
Completed
Not Applicable

A Prospective, Open-Labelled, Single-Center, Two-Arm, Randomized Clinical Study to Compare Patient Satisfaction and Clinical Outcome Associated With Two Nasal Packs (VELNEZ Vs NASOPORE) in Nasal Surgery

Ayu, Inc.1 site in 1 country20 target enrollmentStarted: September 11, 2024Last updated:

Overview

Phase
Not Applicable
Status
Completed
Sponsor
Ayu, Inc.
Enrollment
20
Locations
1
Primary Endpoint
Clinical Success of Nasal Pack

Overview

Brief Summary

This clinical trial evaluated two absorbable nasal packing materials - VELNEZ and NASOPORE - in adult patients (18-70 years) who underwent nasal surgery, including septoplasty, FESS, or turbinoplasty.

The study addressed two core questions: whether VELNEZ offered superior haemorrhage control and faster biodegradation, and whether it reduced postoperative pain, fibrosis, adhesion, and discomfort compared to NASOPORE.

Participants were randomised to receive either packing material following surgery. They were monitored on the day of surgery for haemostasis and device performance, then followed up with clinical and endoscopic assessments - including pain scoring and adverse event tracking - through Day 90.

Detailed Description

This study was a prospective, randomised, open-label, single-centre, two-arm parallel clinical investigation conducted in a post-market setting. It was designed to evaluate and compare the clinical performance of two biodegradable nasal packing materials - VELNEZ and NASOPORE - following routine nasal surgical procedures under real-world conditions.

Rationale and background Nasal packing is routinely employed after septoplasty, FESS, and turbinoplasty to achieve haemostasis, support mucosal healing, and prevent postoperative complications including adhesions and septal haematoma. Conventional non-absorbable packing materials, while effective for haemostasis, are associated with significant patient discomfort, pain at removal, mucosal trauma, and risk of delayed healing. Biodegradable alternatives were developed to address these limitations by obviating the need for mechanical removal and providing a more favourable postoperative environment.

Investigational devices VELNEZ is a biodegradable composite nasal packing material comprising gelatin, chitosan, polyvinyl alcohol, and psyllium husk. Following placement, it was designed to fragment and gradually dissolve within the nasal cavity over several days. Its composition was intended to deliver effective haemostasis, physically separate mucosal surfaces to reduce adhesion formation, and support tissue regeneration - all without requiring removal, thereby minimising procedure-related trauma and improving patient tolerability.

NASOPORE is a biosynthetic, biodegradable polyurethane foam with established clinical use. Its hydrophilic properties allowed it to absorb fluids and conform to the contours of the nasal cavity, providing mechanical support and haemostatic function. Degradation occurred through fragmentation over time, though the rate and completeness of dissolution varied across patients.

Study design and randomisation Participants were assigned in a 1:1 ratio to receive either VELNEZ or NASOPORE as postoperative nasal packing immediately following surgery. Randomisation was performed to minimise selection bias. Given the physical and visual differences between the two materials, blinding of investigators and participants was not feasible; the study was therefore conducted in an open-label manner.

Clinical assessments and follow-up

Assessments were conducted perioperatively and at scheduled postoperative visits through the final follow-up at Day 90. The evaluation framework covered the following domains:

Device performance: Ease of placement, conformability to nasal anatomy, and haemostatic effectiveness were assessed perioperatively. Degradation profile was monitored clinically at each follow-up; irrigation or manual intervention was performed where incomplete dissolution was observed.

Mucosal and structural healing: Endoscopic examination of the surgical site was performed at applicable visits to evaluate mucosal condition, presence of oedema, secretions, fibrosis, scar formation, and adhesion development. Any pressure-related discomfort or structural changes were documented.

Patient-reported outcomes: Symptom burden and quality of life were assessed using the Sino-Nasal Outcome Test (SNOT-22), a validated instrument for sinonasal conditions. Pain and tolerability were evaluated using standardised pain assessment scales at defined time points.

Safety monitoring: Adverse events and serious adverse events were recorded throughout the study. Device-related complications - including infection, hypersensitivity reactions, and signs of delayed healing - were specifically monitored. Vital signs, physical examinations, and laboratory evaluations were conducted per routine clinical practice.

Statistical approach Continuous variables were summarised using descriptive statistics and compared between groups using parametric or non-parametric tests, selected based on data distribution. Categorical variables were analysed using Chi-square or Fisher's exact test, as appropriate. All analyses were conducted at a two-sided significance level.

Ethical and regulatory conduct The study was conducted in accordance with Good Clinical Practice (GCP) and the ethical principles of the Declaration of Helsinki. Institutional Ethics Committee approval was obtained prior to initiation. All participants provided written informed consent before enrolment.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Days to 70 Days (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Participants must meet all of the following criteria were include:
  • Male or female participants aged 18 to 70 years Planned to undergo nasal surgery (e.g., septoplasty, functional endoscopic sinus surgery, or turbinoplasty) requiring postoperative nasal packing Willing and able to comply with all study procedures and follow-up visits Able to understand the study requirements and provide written informed consent

Exclusion Criteria

  • Participants meeting any of the following criteria was be excluded:
  • Known hypersensitivity or allergy to any component of the nasal packing materials (e.g., gelatin, chitosan, polyurethane, or related substances) Active nasal or systemic infection at the time of surgery that may interfere with study outcomes History of bleeding disorders or coagulopathy that may affect haemostasis Use of anticoagulant or antiplatelet therapy that cannot be safely discontinued prior to surgery (as per investigator judgment) Previous nasal surgery or structural abnormalities that may interfere with evaluation of study endpoints Presence of significant comorbid conditions that, in the opinion of the investigator, may affect study participation or outcome assessment Pregnant or lactating women Participation in another clinical study within the last 30 days prior to enrollment Any condition that, in the investigator's opinion, makes the participant unsuitable for inclusion in the study

Arms & Interventions

Arm 1: VELNEZ Nasal Pack

Experimental

Participants undergoing planned nasal surgery received the VELNEZ biodegradable nasal pack, applied intraoperatively or immediately postoperatively in accordance with standard surgical practice. The device was intended to provide haemostasis, support mucosal healing, and reduce postoperative complication

Intervention: VELNEZ Nasal Pack (Device)

Arm 2: NASOPORE Nasal Pack

Active Comparator

Participants undergoing planned nasal surgery received the NASOPORE biodegradable nasal pack, applied intraoperatively or immediately postoperatively in accordance with standard surgical practice. The device was intended to provide haemostasis and structural support within the nasal cavity during the healing process.

Intervention: NASOPORE Nasal Pack (Device)

Outcomes

Primary Outcomes

Clinical Success of Nasal Pack

Time Frame: Up to Day 90 post-surgery

Proportion of participants achieved successful clinical outcome defined as complete degradation of the nasal pack within 7 days without device-related adverse events, along with acceptable levels of fibrosis and scar formation, absence of moderate to severe postoperative pain, and no significant breathing discomfort due to pressure effect

Secondary Outcomes

  • Postoperative Pain Assessment(From Day 0 to 14 post- nasal surgery)
  • Time to Haemorrhage Control(Day 0 (Intraoperative))
  • Adhesion Formation (Endoscopic Assessment)(Up to Day 90 post-surgery on post surgery follow up visits)
  • Endoscopic Healing Assessment(From Day 7 to Day 90 post-surgery)
  • Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)(From Day 0 to Day 90 post-surgery)

Investigators

Sponsor
Ayu, Inc.
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials